Sara A.

Vice President - Global Head Of Rare Disease Commercial Strategy- Assets, Brands And Care Solutions at UCB

Sara A. has an extensive work experience in the pharmaceutical and healthcare industry. Sara currently holds the position of Vice President - Global Head of Rare Disease Commercial Strategy- Assets, Brands and Care Solutions at UCB since February 2022. Prior to this role, they served as the VP & Chief of Staff Rare Disease and Head of Global Medical Affairs - Managed Access and Medical Communications at UCB.

In addition to their experience at UCB, Sara A. also worked as a Certified Hospice at La Maison de Tara starting in September 2021. Before that, they established their own consultancy firm, Sara R Aswegan LLC, in 2017, providing strategic guidance and consulting services in the areas of global drug development, communications, launch, and commercialization strategies for rare diseases. Sara has also served as Faculty & Advisor at the Institute for Biomedical Entrepreneurship, Inc.

Sara A. has held notable leadership positions in the past, including Chief Commercial Officer and Managing Director at Backpack Health, A Konica Minolta Service, and Senior Vice President Global Product Strategy at Ultragenyx Pharmaceutical Inc.

Sara'stenure at Shire includes roles as Vice President, PSTL & Head New Products, GI BU, Senior Director, Global Franchise Commercial Lead, MPS Franchise, and Vice President, Product Strategy Team Lead MPS - Elaprase & SHP - 609 Rare Disease Business Unit. Sara also held positions at Shire HGT as Director, Global Strategic Marketing and Director, Marketing North America.

Sara A. began their career in marketing at APUS in 2006.

Sara A. has a diverse education history. In 1993-1997, they obtained a BA in Business & Communications from the University of Nebraska-Lincoln. In 2010, they completed an Exec Education program in Health Economics and Outcomes at Harvard University School of Public Health. In 2017, they received a Certificate in Digital Marketing: Customer Engagement, Social Media, Planning & Analytics from Columbia Business School. In 2020-2021, Sara attended IMD for Leadership Mastery. Currently, they are pursuing a Certificate in Enterprise Risk Management from the Institute of Risk Management, with an expected completion date in June 2024.

Links

Previous companies

Ultragenyx Pharmaceutical logo

Timeline

  • Vice President - Global Head Of Rare Disease Commercial Strategy- Assets, Brands And Care Solutions

    February, 2022 - present

  • VP & Chief Of Staff Rare Disease

    January, 2021

  • Head Of Global Medical Affairs -managed Access And Medical Communications | Rare Disease

    February, 2020